Comparing the current results to its competitors, Agile Therapeutics Inc reported Revenue decrease in the 2 quarter 2024 year on year by -2.23 %, despite the revenue increase by the most of its competitors of 18.26 %, recorded in the same quarter.
Agile Therapeutics Inc, slower than the average decrease reported by the company's competitors of -5.77 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -5.77 %
Agile Therapeutics Inc's Comment on Competition and Industry Peers
The contraceptive products industry is characterized by significant competition from large pharmaceutical companies, specialty pharmaceutical firms, generic drug manufacturers, and medical device companies. The company competes with various non-permanent birth control methods, including non-hormonal barrier methods such as contraceptive sponges, diaphragms, cervical caps or shields, and condoms, as well as hormonal methods including oral contraceptives, injections, implants, hormonal intrauterine devices (IUDs), vaginal rings, and transdermal contraceptive products. Key competitors include Organon, which markets Nuvaring®; Mayne Pharmaceuticals, marketing Annovera® and Nextstellis®; Allergan (formerly Actavis), marketing the Loestrin® franchise; Bayer, marketing Beyaz®, Yaz®, Yasmin®, and Natazia®; Viatris, marketing Xulane®; Evofem, developer of Phexxi®; Mithra Pharmaceuticals, developer of Nextstellis®; and the Population Council, which is developing a transdermal gel contraceptive and a vaginal ring contraceptive. Corium Innovations, Inc. serves as the contract manufacturer for Twirla.
January 23, 2024
The Biden-Harris Administration has recently announced new guidance that aims to expand access to all FDA-approved contraceptives without cost. This development has significant implications for the pharmaceutical industry and women s reproductive health, particularly for innovative products like Twirla, a contraceptive patch developed by Agile Therapeutics Inc. Coinciding with this news, Agile Therapeutics Inc reported a remarkable revenue increase in the third quarter of 2023, outperforming its competitors by a significant margin.Expanding Access to Contraceptive Products:The Biden-Harris Administration s latest guidance is a notable milestone in the pursuit of affordable contraceptive options for all women...
Harmony Biosciences Holdings Inc's business model revolves around the development and commercialization of innovative therapies for patients with sleep disorders.
Myovant Sciences Ltd operates under a biopharmaceutical business model primarily focused on the development and commercialization of therapies for women's health and prostate cancer. The company aims to leverage its expertise in clinical research, regulatory affairs, and manufacturing to bring innovative treatments to market and improve patients' lives. Myovant Sciences employs a combination of in-house research and development along with collaboration with strategic partners to advance its pipeline of product candidates.
Puma Biotechnology Inc operates as a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for the treatment of cancer. Their business model revolves around identifying promising preclinical and clinical drug candidates, conducting rigorous research and development, and seeking regulatory approval for their products. Puma Biotechnology Inc strives to effectively market and distribute their approved therapeutics to provide patients with potentially life-saving treatment options.
Perrigo Company Plc is a leading global healthcare supplier that focuses on providing affordable, high-quality over-the-counter (OTC) healthcare and wellness products. The company operates through its own worldwide distribution network, manufacturing a wide range of products and medications. By leveraging its extensive portfolio and efficient supply chain, Perrigo aims to enhance the well-being of consumers by making quality healthcare products more accessible.
Teva Pharmaceutical Industries Limited is a multinational pharmaceutical company that focuses on the development, production, and marketing of generic and specialty medicines. They aim to provide affordable and accessible healthcare solutions to patients worldwide.
Sources:
Agile Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Agile Therapeutics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
